MGF, or mechano growth factor, is a splice variant of insulin-like growth factor 1 (IGF-1Ec in humans) that skeletal muscle produces in response to mechanical loading and damage. The established science treats it as an early-phase repair signal studied mostly in cell-culture and animal models, while the injectable synthetic version sold in research-peptide and bodybuilding markets rests on far thinner human evidence. It carries no regulatory approval for human use, is sold only under research-use-only labeling, and is banned in sport.
MGF is the IGF-1Ec splice variant of IGF-1, produced locally in loaded muscle as an early repair signal, and its injectable synthetic form carries no regulatory approval, sells only under research-use-only labeling, and is banned in sport.
Mechano growth factor is best understood not as a separate hormone but as one of the proteins the IGF-1 gene produces through alternative splicing. When a muscle cell is overloaded or damaged, transcription shifts toward the IGF-1Ec variant, which carries an unusual C-terminal E-domain; that E-domain is what separates MGF from the mature IGF-1 circulating in blood, and the short synthetic peptides sold commercially correspond to the E-domain rather than the full molecule.
MGF acts as a local, autocrine or paracrine repair signal produced by the IGF-1Ec splice variant, appearing as a rapid early pulse within hours of mechanical loading rather than circulating systemically like mature IGF-1.
The role most consistently attributed to MGF sits at the front of the repair sequence, not at the growth end of it. The published picture describes a two-stage division of labor: MGF supplies the fast early activation signal, and the later, sustained IGF-1 expression drives the differentiation and protein-synthesis phase that actually enlarges the fiber. On hypertrophy specifically, the evidence points more clearly to a repair and satellite-cell activation role than to a proven driver of muscle enlargement in humans.
In the published two-stage model of repair, MGF provides the early satellite-cell activation signal while sustained IGF-1 drives the later growth phase, and the evidence supports a repair role for MGF more than a proven driver of human muscle enlargement.
The practical difference between MGF and PEG-MGF comes down to how long the peptide survives in the body. Native MGF and its synthetic E-domain counterpart degrade within minutes, which fits a brief local repair signal but makes an injected product awkward; pegylation attaches a polyethylene glycol chain that shields the peptide from enzymatic breakdown and extends its half-life from minutes to hours or days.
| Property | MGF | PEG-MGF |
|---|---|---|
| Half-life | Minutes | Hours to days |
| Intended use | Localized post-exercise injection near a worked muscle | Systemic, longer-acting signal across the body |
| Rationale | Mimic the natural local pulse | Reconcile with an infrequent injection schedule |
| Market prominence | Less common | The more prominent of the two |
Pegylation extends MGF's half-life from minutes to hours or days, which is why PEG-MGF is marketed as a systemic, longer-acting form and is the more prominent of the two in the research-peptide market, even though extending a naturally local, transient signal departs from how the molecule behaves physiologically.
MGF and IGF-1 are two products of the same gene rather than unrelated molecules, and the contrast that matters most is behavioral. Mature IGF-1 is the systemic, durable endocrine growth factor produced largely by the liver under growth-hormone control, while MGF, the IGF-1Ec splice variant, is the local, muscle-produced, short-acting counterpart defined by its E-domain.
MGF and IGF-1 are splice products of the same gene distinguished by behavior, with IGF-1 acting as a systemic, durable growth factor and MGF as a local, short-acting early-repair signal, unlike engineered analogs such as IGF-1 LR3 or the separate FGF and HGF protein families.
The evidence for MGF splits sharply by question. As muscle biology, endogenous MGF is genuinely supported: cell-culture and animal studies show the IGF-1Ec variant is upregulated by mechanical loading and that the E-domain peptide can promote satellite-cell proliferation and cell survival. What is largely missing is the part that matters most to a consumer, controlled human trials showing that injecting synthetic MGF or PEG-MGF produces meaningful gains in size, strength, or recovery.
Endogenous MGF is supported by cell-culture and animal evidence for satellite-cell proliferation and survival, but no rigorous controlled human trials show that injected synthetic MGF or PEG-MGF improves muscle size, strength, or recovery, so most market efficacy claims extrapolate from mechanism and animal data.
How MGF is handled in research settings is documentation, not guidance, because MGF is not an approved medicine and no legitimate clinical dosing exists for it. Research-grade material is supplied as a lyophilized powder reconstituted with a sterile diluent such as bacteriostatic water, and because the peptide is fragile it is generally kept refrigerated once mixed and stored frozen in powder form. The dosing figures circulating in research-peptide communities are informal conventions rather than validated protocols.
In research settings MGF is documented as a lyophilized powder reconstituted with bacteriostatic water, refrigerated once mixed and stored frozen as powder, but because it is sold outside pharmaceutical oversight its purity, sequence accuracy, and sterility vary by supplier and cannot be assumed.
The safety profile of MGF is dominated by uncertainty rather than a well-characterized side-effect list, and that uncertainty is itself the main risk. With no substantial human safety trials of injectable MGF, the potential harms are largely theoretical and inferred from what is known about growth factors generally.
MGF's human safety is not established, and the combination of a growth-promoting mechanism with a theoretical tumor-related concern, an unregulated product prone to wrong sequence or contamination, and unsupervised self-injection means its risks cannot be quantified or dismissed.
MGF occupies the same gray zone as most research peptides: neither an approved drug nor a legitimate dietary supplement. No major regulator, including the U.S. Food and Drug Administration, has approved MGF or PEG-MGF for any human medical use, and what keeps it on the market is research-use-only labeling that frames it as a laboratory reagent not intended for human consumption.
No major regulator, including the FDA, has approved MGF or PEG-MGF for human use; it is sold only under research-use-only labeling, is prohibited in sport by the World Anti-Doping Agency at all times, and its import or possession carries jurisdiction-dependent legal risk.
Interest in MGF clusters into a few groups on very different footing. The largest consumer-facing audience is bodybuilders and strength athletes drawn by the promise of faster repair and recovery, while a separate and more legitimate group is researchers studying muscle regeneration, aging, and tissue repair for whom MGF is a signaling molecule rather than a product to consume. What unites the consumer side is that expectations are shaped by marketing and mechanism-based reasoning rather than demonstrated human outcomes.
Bodybuilders and strength athletes make up MGF's largest consumer audience alongside injury-recovery and anti-aging interest, yet their expectations rest on marketing and mechanism-based reasoning rather than demonstrated human outcomes, unlike researchers who treat MGF as a signaling molecule rather than a product.
Educational use only. This article describes what the published scientific and clinical literature reports about MGF. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
